Tadenan treatment of prostatic adenoma
- Autores: Danilov VV1, Eliseeva EV1, Vasil'chenko AV1, Danilov VV1, Eliseeva EV1, Vasilchenko AV1
-
Afiliações:
- Edição: Nº 2 (2009)
- Páginas: 68-73
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/277407
- ID: 277407
Citar
Texto integral
Resumo
Tadenan, a drug of plant origin, was given to 27 patients with documented prostatic adenoma for 3-12 months. Home uroflowmonitoring for 1, 3, 6 and 12 months registered positive changes in urinary flow rate and urination volume. Side effects were absent. IPSS and QoL parameters were also assessed.
Bibliografia
- Kirby R., ed. Textbook of benign prostatic hyperplasia. Oxford; 1996. 331-337.
- Breza J., Dzurny O., Borowka A. et al. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr. Med. Res. Opin. 1998; 14 (3): 127-139.
- Desgrandchamps F. Clinical relevance of growth factor antagonists in the treatment of benign prostatic hyperplasia. Eur. Urol. 1997; 32 (suppl. 1): 28-31.
- Levin R. M., Levin S. S., Zhao Y., Buttyan R. Cellular and molecular aspects of bladder hypertrophy. Eur. Urol. 1997; 32 (suppl. 1): 15-21.
- Levin R. M., Das A. K. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol. Res. 2000; 28 (3): 201-209.
- Вишневский Е. Л. и др. Урофлоуметрия. М.: Печатный город; 2004.
Arquivos suplementares
